Applying Fusion Protein Technology to E. Coli - - BioPharm International

ADVERTISEMENT

Applying Fusion Protein Technology to E. Coli


BioPharm International


19. Shih YP, Kung WM, Chen JC, Yeh CH, Wang AH, Wang TF. High-throughput screening of soluble recombinant proteins. Protein Sci. 2002; 11(7):1714-1719.

20. Dyson MR, Shadbolt SP, Vincent KJ, Perera RL, McCafferty J. Production of soluble mammalian proteins in Escherichia coli: identification of protein features that correlate with successful expression. BMC Biotechnol. 2004; 4:32.

21. De Marco V, Stier G, Blandin S, de Marco A. The solubility and stability of recombinant proteins are increased by their fusion to NusA. Biochem. Biophys. Res. Commun. 2004; 322:766-771.

22. Sharma SK, Evans DB, Vosters AF, McQuade TJ, Tarpley WG. Metal affinity chromatography of recombinant HIV-1 reverse transcriptase containing a human renin cleavable metal binding domain. Biotechnol. Appl. Biochem. 1991; 14:69-81.

23. Di Guan C, Li P, Riggs PD, Inouye H. Vectors that facilitate the expression and purification of foreign peptides in Escherichia coli by fusion to maltose-binding protein. Gene. 1988; 67:21-30.

24. Smith DB, Johnson KS. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione-S-transferase. Gene. 1988; 67:31-40.

25. Makrides AC. Strategies for achieving high-level expression of genes in Escherichia coli. Microbiol. Reviews. 1996; 60:512-538.

26. Narum DL, Kumar S, Rogers WO, Fuhrmann SR, Liang H, Oakley M, et al. Codon optimization of gene fragments encoding Plasmodium falciparum merzoite proteins enhances DNA vaccine protein expression and immunogenicity in mice. Infect. Immun. 2001; 69:7250-3.

27. Brinkmann U, Mattes RE, Buckel P. High-level expression of recombinant genes in Escherichia coli is dependent on the availability of the dnaY gene product. Gene. 1989; 85:109-114.

28. Butt TR, Jonnalagadda S, Monia BP, Sternberg EJ, Marsh JA, Stadel JM, et al. Ubiquitin fusion augments the yield of cloned gene products in Escherichia coli. Proc. Natl. Acad. Sci. 1989; 86:2540-4.

29. Dubendorff JW, Studier FW. Controlling basal expression in an inducible T7 expression system by blocking the target T7 promoter with the lac repressor. J. Mol. Biol. 1991; 219:45-59.

30. Thiem SM, Miller LK. Differential gene expression mediated by late, very late and hybrid baculovirus promoters. Gene. 1980; 91:87-94.

31. Sachdev D, Chirgwin JM. Fusions to maltose-binding protein: Control of folding and solubility in protein purification. Methods Enzymol. 2000; 326:321-321.

32. Arechaga I, Miroux B, Runswick MJ, Walker JE. Over-expression of Escherichia coli F1F(o)-ATPase subunit a is inhibited by instability of the uncB gene transcript. FEBS Lett. 2003; 547;97-100.

33. Prinz A, Aslund F, Holmgren A, Beckwith J. The role of the thioredoxin and glutaredoxin pathways in reducing protein disulfide bonds in the Escherichia coli cytoplasm. J. Biol. Chem. 1997; 272:15661-7.

34. Ikura K, Kokubu T, Natsuka S, Ichikawa A, Adachi M, Nishihara K, et al. Co-overexpression of folding modulators improves the solubility of the recombinant guinea pig liver transglutaminase in Escherichia coli. Prep. Biochem. Biotechnol. 2002; 32:189-205.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

New Tax Rules May Deter Future Pharma M&A
October 1, 2014
NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
Author Guidelines
Source: BioPharm International,
Click here